Notably, mutation rates for genes targeted by drugs were increased by UNCeqRMETA, specifically, PIK3CA, FGFR2 and ERBB2. Therefore, UNCeqRMETA largely advanced published, state-of-the-art mutation profiles with cancer-relevant mutations by utilizing the integration of RNA-seq and DNA-WES. The gene discussed is ERBB2; the disease is cancer.